Fortress Biotech Inc 9.375% Series A Cumulativ (FBIOP) Stock Price, Quote & News

Company Profile

Fortress Biotech, Inc., a biopharmaceutical company, engages in the development and commercialization of biopharmaceutical products. The company markets dermatology products, including Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for inflammatory lesions of non-n...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 652 4500

Website: www.fortressbiotech.com

Address:

1111 Kane Concourse, Suite 301, Bay Harbor Islands, United States

Zellchair Sep. 2 at 8:17 PM

$FBIO $FBIOP Until then all Haters: Does my Fortress exposure (in this stock-only account) look a little better today? Hopefully a long, long way to go before I sell my shares. Best Regards/ "The Bear"

1 · Reply

Zellchair Sep. 2 at 8:09 PM

$FBIO $FBIOP Then I ask for some leniency with the time difference as the stock market in the US closes at 10:00 pm here in the evening local time. I hope and believe that I can get the text out tomorrow if nothing unexpected happens.

1 · Reply

Zellchair Sep. 2 at 7:56 PM

$FBIO $FBIOP At least Eli Lilly hasn't closed the doors to buying any available PRV on the market, it seems... https://x.com/PRVWatch/status/1960380836097688022

0 · Reply

Zellchair Sep. 2 at 7:06 PM

$FBIO $FBIOP "Spill the bean already" This is exactly what I've been talking about for almost 2 years here. Those who do their homework and search and read will gain advantages. The results are out there, ready for everyone to read for those who can find them. If you want to take the shortcut (not recommended) and read my text, you'll have to be patient. Given the scope of the text in length and the effort to go through the results, you'll understand that it takes time. I'm not an AI, but, if you like what you've seen of Fortress so far, I think you'll be pleasantly surprised when the text is released if it's still news to you then.

1 · Reply

FinSUN Sep. 2 at 5:31 PM

$FBIO $FBIOP

0 · Reply

makrodimutross Sep. 2 at 5:17 PM

$FBIO $FBIOP since this post, commons are up Another 40%, and preferreds only 11%. @FinSUN i do formally declare you correct on this. I was wrong. The suspended dividends don't appear to be a concern for prospective buyers of the common stock. Good luck all longs.

0 · Reply

Zellchair Sep. 2 at 4:39 PM

$FBIO $FBIOP This is a major contributing factor to the increased volume and price increase. News that came last Friday.

0 · Reply

Zellchair Sep. 2 at 4:21 PM

$FBIO $FBIOP Writing more frantically than a mouse trying to escape from a pre-clinical study... Perhaps the best find I've ever found about Fortress ever.

1 · Reply

Airbags Sep. 2 at 4:13 PM

$FBIOP $FBIO $TNXP The video I was trying to share in my last post.

0 · Reply

TheBiotechInvestor_ Sep. 2 at 3:46 PM

$FBIO $FBIOP Share with your family, friends, and your enemies as well 😂

0 · Reply

Fortress Biotech to Present at the H.C. Wainwright 27th Annual Global Investment Conference

FBIO

Aug 14, 2025, 4:05 PM EDT - 19 days ago

Fortress Biotech Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

FBIO

May 30, 2025, 10:47 AM EDT - 3 months ago

Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics

FBIO

May 15, 2025, 4:05 PM EDT - 3 months ago

Fortress Biotech Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

FBIO

May 7, 2025, 8:00 AM EDT - 4 months ago

Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference

FBIO

Mar 26, 2025, 7:39 PM EDT - 5 months ago

Fortress Biotech, Inc. (FBIO) Q4 2024 Earnings Call Transcript

FBIO

Mar 17, 2025, 8:55 AM EDT - 6 months ago

Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform

FBIO

Jan 27, 2025, 8:30 AM EST - 7 months ago

Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT

FBIO

Jan 6, 2025, 8:00 AM EST - 8 months ago

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease

FBIO

Nov 14, 2024, 4:10 PM EST - 10 months ago

Fortress Biotech Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights

FBIO

Sep 26, 2024, 8:30 AM EDT - 1 year ago

Fortress Biotech to Participate in October 2024 Investor Conferences

FBIO

Sep 20, 2024, 8:30 AM EDT - 1 year ago

Fortress Biotech Announces Pricing of $8 Million Registered Direct Offering and Concurrent Private Placements

FBIO

Sep 4, 2024, 8:30 AM EDT - 1 year ago

Fortress Biotech to Present at the H.C. Wainwright 26th Annual Global Investment Conference

FBIO

Aug 13, 2024, 4:05 PM EDT - 1 year ago

Fortress Biotech Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

FBIO

Jul 25, 2024, 8:30 AM EDT - 1 year ago

Fortress Biotech Reduces Total Debt and Enters into New $35 Million Term Loan with Oaktree with Maturity in 2027

FBIO

Jul 5, 2024, 4:05 PM EDT - 1 year ago

Fortress Biotech Announces Pause in Payment of Dividends on 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock

FBIO

Nov 10, 2022, 10:42 PM EST - 3 years ago

Fortress Biotech, Inc. (FBIO) Q3 2022 Earnings Call Transcript

FBIO

Aug 9, 2022, 9:05 PM EDT - 3 years ago

Journey Medical Corporation (FBIO) CEO Claude Maraoui on Q2 2022 Results - Earnings Call Transcript

FBIO

Mar 19, 2019, 12:01 PM EDT - 7 years ago

Plenty Of Further Upside In Fortress Biotech

FBIO

Zellchair Sep. 2 at 8:17 PM

1 · Reply

Zellchair Sep. 2 at 8:09 PM

1 · Reply

Zellchair Sep. 2 at 7:56 PM

$FBIO $FBIOP At least Eli Lilly hasn't closed the doors to buying any available PRV on the market, it seems... https://x.com/PRVWatch/status/1960380836097688022

0 · Reply

Zellchair Sep. 2 at 7:06 PM

1 · Reply

FinSUN Sep. 2 at 5:31 PM

$FBIO $FBIOP

0 · Reply

makrodimutross Sep. 2 at 5:17 PM

0 · Reply

Zellchair Sep. 2 at 4:39 PM

$FBIO $FBIOP This is a major contributing factor to the increased volume and price increase. News that came last Friday.

0 · Reply

Zellchair Sep. 2 at 4:21 PM

$FBIO $FBIOP Writing more frantically than a mouse trying to escape from a pre-clinical study... Perhaps the best find I've ever found about Fortress ever.

1 · Reply

Airbags Sep. 2 at 4:13 PM

$FBIOP $FBIO $TNXP The video I was trying to share in my last post.

0 · Reply

TheBiotechInvestor_ Sep. 2 at 3:46 PM

$FBIO $FBIOP Share with your family, friends, and your enemies as well 😂

0 · Reply

denisehurst_ Sep. 2 at 3:08 PM

$FBIOP UTRX shows treasury ALM policy key access controls third party audits and counterparty limits. No sensitive details just processes and cadence of reviews.

0 · Reply

Airbags Sep. 2 at 2:04 PM

$TNXP move to $FBIO.. best move in weeks, wish I did it sooner. $FBIO has the right people in place and experience. $FBIOP is a good indicator of that. TNXP gave me a pretty good run, but shows how much a difference good management and updates can make.

0 · Reply

Zellchair Sep. 2 at 10:44 AM

$FBIO $FBIOP This should of course not be underestimated in the context. When David can measure himself against Goliath, etc.

0 · Reply

Zellchair Sep. 2 at 10:10 AM

$FBIO $FBIOP This can of course be changed for the very, in my opinion, logical reason that Mineralys will now be acquired in the future. It doesn't matter if you have a comparable drug when you have to compete against AstraZeneca sales with all its already established sales channels when you lack these yourself.

0 · Reply

Zellchair Sep. 2 at 10:05 AM

$FBIO $FBIOP However, on Sunday I realized that the market would probably have greater expectations for Baxdrostat (despite a more convincing overall picture in the data when combining efficacy and safety) given that the market itself is more than large enough in the future (which is important to remember regarding Dotinurad's Asia studies in the indication of a non-direct competitor). This made me delete my post. This was confirmed yesterday given AstraZeneca's market reaction (the stock is listed, given its origin, in both the UK and Sweden) and seems more than confirmed by the pre-trade in Mineralys today. So we have a potential reverse potential scenario that I initially wrote in my substack, i.e. now even "richer" BT.S. but with potentially less focus, priority and with greater conflict of interest in the future for Crystalys and its Dotinurad.

0 · Reply

Zellchair Sep. 2 at 10:03 AM

$FBIO $FBIOP I deleted my AstraZeneca vs Mineralys dubstack post on Sunday when I reviewed the data between Baxdrostat and Lorundrostat more closely. The safety data favors Baxodrostat, and with comparable efficacy data, I initially thought Lorundrostat (Mineralys) would tank today: "But AstraZeneca's Dobber notes baxdrostat has a significantly longer half-life than lorundrostat. It stays in the body for longer, meaning patients are protected from high blood pressure all day. Goldman Sachs' Sharma notes baxdrostat's half-life is 26 to 31 hours, vs. 10 to 12 hours for lorundrostat. 'If you have a longer half-life, that supports consistent 24-hour control of blood pressure including overnight when patients are most vulnerable to cardiovascular events,' Dobber said." https://www.investors.com/news/technology/astrazeneca-hypertension-blood-pressure-baxdrostat-mineralys-therapeutics/ https://x.com/semodough/status/1962277828889563282

0 · Reply

Zellchair Sep. 2 at 9:06 AM

$FBIO $FBIOP If Fortress doesn't send out a press release regarding one of their drugs in their subsidiary's pipeline before opening today, I will start writing on a new substack. For various reasons, I assess the chance of a press release very low. The post, if published, probably cannot be interpreted from a negative view of Fortress even if you try. No bears in sight here, in other words.

2 · Reply

Zellchair Aug. 31 at 10:27 PM

$FBIO $FBIOP $DERM Last one. The person that still can't understand that I blocked both of his accounts... But okay, report me instead.

0 · Reply

Zellchair Aug. 31 at 8:52 PM

$FBIO $FBIOP I finally had enough and the block feature will be active. Just want to clarify that I have never and will never sell anything. You can't even pay for my substack posts even if you find some value in it as that feature isn't even turned on. LONG FBIO & FBIOP

0 · Reply

Zellchair Aug. 31 at 7:49 PM

$FBIO $FBIOP "Spreading Fortress is worthless / no royalties / no PRV upside” If you had actually bothered to read, you might have understood that I write exactly the opposite. Look at the end of my CUTX-101 review in the picture, for example. Still bearish?

0 · Reply

stonkgeeker Aug. 31 at 7:47 PM

$FBIO $FBIOP at this point, no one gives a shit if you are bearish or bullish. We all know you’re fucking annoying.

0 · Reply

Zellchair Aug. 31 at 7:42 PM

$FBIO $FBIOP Last. Again only this year in FBIO. The number of purchases in 2024 was several times more. As you can see, the purchases decrease at the end, as I switch to buying more FBIOP instead. But I made 2 purchases in FBIO as late as this week (26 august). Do you still think I'm bearish?

0 · Reply

Market Cap	N/A
Revenue (ttm)	84.51M
Net Income (ttm)	-60.64M
EPS (ttm)	N/A
PE Ratio	N/A
Forward PE	N/A
Profit Margin	N/A
Debt to Equity Ratio	N/A

Volume	304
Avg Vol	18,892
Day's Range	N/A - N/A
Shares Out	N/A
Stochastic %K	79%
Beta	N/A
Analysts	Strong Buy
Price Target	N/A